Ema CHMP issues positive opinion for label updates to Takeda's Vipidia, Vipdomet and Incresync
Takeda Pharmaceuticals International GmbH today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has issued positive opinions for updates to the Summary of Product Characteristics for VipidiaTM and the fixed-dose combination therapies VipdometTM and IncresyncTM .
The Ghosts of Litigation Holds Past
Earlier this year, in the widely followed In re: Actos Products Liability Litigation matter, a Louisiana federal jury ordered a drug manufacturer to pay $6 billion in punitive damages and $1.5 million in actual damages.
Diabetes Drug Pioglitazone May Lower Risk of Alzheimer's Disease
According to a report from Reuters, a new German study has suggested that treatment with the diabetes drug pioglitazone may reduce the risk of developing Alzheimer's disease , although conclusive proof could be years away.
German database study hints diabetes drug cuts Alzheimer's risk
A large German study is the latest clinical trial to suggest that a cheap generic treatment for diabetes can stave off symptoms of Alzheimer's disease, although conclusive proof from a more formal trial could be about five years away.
Takeda Pharmaceutical Co. Ltd. And Zinfandel Pharmaceuticals Inc. To ...
Takeda Pharmaceutical Company Limited and its partner, Zinfandel Pharmaceuticals, Inc. , will present data during multiple poster and oral sessions at the upcoming Alzheimer's Association International ConferenceA 2014 , taking place in "Studies show that individuals with mild cognitive impairmenta slight, although noticeable and measurable decline ... (more)